GioTag is a non-interventional study based on existing medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib as the first-line treatment followed by osimertinib for T790M resistance mutation patients. In this paper find out the results of this observational real-world study and how the findings could increase our understanding of how sequencing of tyrosine kinase inhibitors can extend chemotherapy-free treatment time.
Aims: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) NSCLC receiving sequential afatinib and osimertinib in a real-world clinical setting.
Patients & methods: In this retrospective, observational, multicenter study, patients (n=204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment.
Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8–not reached) in Asians. Two-year overall survival was 78.9%.
Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors.